Cargando…

Duffy and Kidd Genotyping Facilitates Pretransfusion Testing in Patients Undergoing Long-Term Transfusion Therapy

Objective: Conventional serologic typing of red blood cell systems other than ABO and RhD can be inaccurate and difficult to interpret in patients who have recently undergone blood transfusion. While molecular-based assays are not used routinely, the usefulness of genotyping was investigated in orde...

Descripción completa

Detalles Bibliográficos
Autores principales: Remeikiene, Diana, Ugenskiene, Rasa, Inciura, Arturas, Savukaityte, Aiste, Raulinaityte, Danguole, Skrodeniene, Erika, Simoliuniene, Renata, Juozaityte, Elona
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Galenos Publishing 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4454051/
https://www.ncbi.nlm.nih.gov/pubmed/25541653
http://dx.doi.org/10.4274/tjh.2013.0075
_version_ 1782374546012110848
author Remeikiene, Diana
Ugenskiene, Rasa
Inciura, Arturas
Savukaityte, Aiste
Raulinaityte, Danguole
Skrodeniene, Erika
Simoliuniene, Renata
Juozaityte, Elona
author_facet Remeikiene, Diana
Ugenskiene, Rasa
Inciura, Arturas
Savukaityte, Aiste
Raulinaityte, Danguole
Skrodeniene, Erika
Simoliuniene, Renata
Juozaityte, Elona
author_sort Remeikiene, Diana
collection PubMed
description Objective: Conventional serologic typing of red blood cell systems other than ABO and RhD can be inaccurate and difficult to interpret in patients who have recently undergone blood transfusion. While molecular-based assays are not used routinely, the usefulness of genotyping was investigated in order to determine patients who may benefit from this procedure. Materials and Methods: Blood samples were taken from 101 patients with haemato-oncological, chronic renal, or gastroenterological diseases and from 50 donor controls; the samples were tested for Fya and Fyb by applying serologic and genetic methods. All patients had received 3 or more units of RBCs during the last 3 months. An average of 6.1 RBC units were transfused per patient. The average length of time from transfusion until blood sampling was 24.4 days. The haemagglutination test was applied for serological analysis, and the restriction length polymorphism assay was used for genotyping. Results: In total, 33 (32.7%) patients showed positive reactions with anti-Fya or anti-Fyb while being negative genetically. False-positive Fya results were found in 23 samples, and false-positive Fyb in 10 specimens. During the last 3 months, significantly more RBC units were transfused to patients with discrepant results than to those with accurate phenotyping/genotyping results: median of 5 (mean ± SE: 6.85±0.69) versus median of 4 (mean: 5.71±0.51), respectively (p=0.025). The median length of time after the last transfusion was 25 days (mean: 28.72±2.23 days) in the group with accurate phenotyping/genotyping results versus a median of 14 days (mean: 15.52±1.95 days) in the group with discrepant results (p=0.001). Phenotypes and genotypes coincided in all donor samples. Conclusion: Genotyping assays for the Duffy system should be considered if the patient underwent blood transfusion less than 3 or 4 weeks before the sample collection. If the time frame from RBC transfusion exceeds 6 weeks, Duffy phenotyping can provide accurate results.
format Online
Article
Text
id pubmed-4454051
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Galenos Publishing
record_format MEDLINE/PubMed
spelling pubmed-44540512016-01-12 Duffy and Kidd Genotyping Facilitates Pretransfusion Testing in Patients Undergoing Long-Term Transfusion Therapy Remeikiene, Diana Ugenskiene, Rasa Inciura, Arturas Savukaityte, Aiste Raulinaityte, Danguole Skrodeniene, Erika Simoliuniene, Renata Juozaityte, Elona Turk J Haematol Research Article Objective: Conventional serologic typing of red blood cell systems other than ABO and RhD can be inaccurate and difficult to interpret in patients who have recently undergone blood transfusion. While molecular-based assays are not used routinely, the usefulness of genotyping was investigated in order to determine patients who may benefit from this procedure. Materials and Methods: Blood samples were taken from 101 patients with haemato-oncological, chronic renal, or gastroenterological diseases and from 50 donor controls; the samples were tested for Fya and Fyb by applying serologic and genetic methods. All patients had received 3 or more units of RBCs during the last 3 months. An average of 6.1 RBC units were transfused per patient. The average length of time from transfusion until blood sampling was 24.4 days. The haemagglutination test was applied for serological analysis, and the restriction length polymorphism assay was used for genotyping. Results: In total, 33 (32.7%) patients showed positive reactions with anti-Fya or anti-Fyb while being negative genetically. False-positive Fya results were found in 23 samples, and false-positive Fyb in 10 specimens. During the last 3 months, significantly more RBC units were transfused to patients with discrepant results than to those with accurate phenotyping/genotyping results: median of 5 (mean ± SE: 6.85±0.69) versus median of 4 (mean: 5.71±0.51), respectively (p=0.025). The median length of time after the last transfusion was 25 days (mean: 28.72±2.23 days) in the group with accurate phenotyping/genotyping results versus a median of 14 days (mean: 15.52±1.95 days) in the group with discrepant results (p=0.001). Phenotypes and genotypes coincided in all donor samples. Conclusion: Genotyping assays for the Duffy system should be considered if the patient underwent blood transfusion less than 3 or 4 weeks before the sample collection. If the time frame from RBC transfusion exceeds 6 weeks, Duffy phenotyping can provide accurate results. Galenos Publishing 2014-12 2014-12-05 /pmc/articles/PMC4454051/ /pubmed/25541653 http://dx.doi.org/10.4274/tjh.2013.0075 Text en © Turkish Journal of Hematology, Published by Galenos Publishing. http://creativecommons.org/licenses/by/2.5/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Remeikiene, Diana
Ugenskiene, Rasa
Inciura, Arturas
Savukaityte, Aiste
Raulinaityte, Danguole
Skrodeniene, Erika
Simoliuniene, Renata
Juozaityte, Elona
Duffy and Kidd Genotyping Facilitates Pretransfusion Testing in Patients Undergoing Long-Term Transfusion Therapy
title Duffy and Kidd Genotyping Facilitates Pretransfusion Testing in Patients Undergoing Long-Term Transfusion Therapy
title_full Duffy and Kidd Genotyping Facilitates Pretransfusion Testing in Patients Undergoing Long-Term Transfusion Therapy
title_fullStr Duffy and Kidd Genotyping Facilitates Pretransfusion Testing in Patients Undergoing Long-Term Transfusion Therapy
title_full_unstemmed Duffy and Kidd Genotyping Facilitates Pretransfusion Testing in Patients Undergoing Long-Term Transfusion Therapy
title_short Duffy and Kidd Genotyping Facilitates Pretransfusion Testing in Patients Undergoing Long-Term Transfusion Therapy
title_sort duffy and kidd genotyping facilitates pretransfusion testing in patients undergoing long-term transfusion therapy
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4454051/
https://www.ncbi.nlm.nih.gov/pubmed/25541653
http://dx.doi.org/10.4274/tjh.2013.0075
work_keys_str_mv AT remeikienediana duffyandkiddgenotypingfacilitatespretransfusiontestinginpatientsundergoinglongtermtransfusiontherapy
AT ugenskienerasa duffyandkiddgenotypingfacilitatespretransfusiontestinginpatientsundergoinglongtermtransfusiontherapy
AT inciuraarturas duffyandkiddgenotypingfacilitatespretransfusiontestinginpatientsundergoinglongtermtransfusiontherapy
AT savukaityteaiste duffyandkiddgenotypingfacilitatespretransfusiontestinginpatientsundergoinglongtermtransfusiontherapy
AT raulinaitytedanguole duffyandkiddgenotypingfacilitatespretransfusiontestinginpatientsundergoinglongtermtransfusiontherapy
AT skrodenieneerika duffyandkiddgenotypingfacilitatespretransfusiontestinginpatientsundergoinglongtermtransfusiontherapy
AT simoliunienerenata duffyandkiddgenotypingfacilitatespretransfusiontestinginpatientsundergoinglongtermtransfusiontherapy
AT juozaityteelona duffyandkiddgenotypingfacilitatespretransfusiontestinginpatientsundergoinglongtermtransfusiontherapy